3188 results for «2113»
3188 results
These EuroIntervention papers changed my practice!
15 May 2024 – From EuroPCR 2024
Bifurcation lesion, interactive case discussion
15 May 2024 – From EuroPCR 2024
Technical pearls in CTO PCI
14 May 2024 – From EuroPCR 2024
This session will feature a series of selected clinical case submissions from EuroPCR 2024, focusing on the technical pearls and innovative approaches in the management of chronic total occlusions (CTO) during percutaneous coronary interventions. Attendees will have the opportunity to explore various strategies, including the use...
The turning point in hypertension care: Symplicity Spyral renal denervation in practice
15 May 2024 – From EuroPCR 2024
Explore this session to grasp the FDA-approved status of renal denervation, its safety and efficacy shown in numerous studies with lasting effects, and the importance of multidisciplinary discussions for successful indications. Consult also the session for updated recommendations on renal denervation in hypertension treatment guidelines, procedural safety...
Innovations in TMVR and Intrepid trial updates
14 May 2024 – From EuroPCR 2024
Tune in to this session for comprehensive updates on APOLLO and Intrepid TF, along with invaluable lessons gleaned. Discover insights on patient screening for Intrepid TMVR, and delve into clinical case reviews highlighting advancements such as updated 29Fr access. Learn about the safety and efficacy of...
Role of deferred stenting in culprit and non-culprit lesions for STEMI
14 May 2024 – From EuroPCR 2024
This session explores the role of deferred stenting in STEMI patients, covering when and how PCI can be deferred, the latest pharmacological options for deferred stenting, and the use of imaging and physiology to guide revascularization in a primary PCI setting. Through case presentations and discussions,...
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
Future directions of drug-coated balloon angioplasty
06 Feb 2025
Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.
Author
Author
